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Infloran capsule showed an identical profile on biochemical, 
mass-spectrometric and molecular analyses, suggesting a di-
rect correlation between the administration of probiotics 
and bacteremia with  B. longum in all 3 infants.  Conclusions: 
The occurrence of bacteremia with bifidobacteria after its 
prophylactic administration in VLBW infants and its possible 
clinical consequences are a matter of concern. In the interests 
of safety, the use of probiotics in such a population should be 
indicated with caution and requires further investigation. 
 © 2014 S. Karger AG, Basel 
 Introduction 
 Necrotizing enterocolitis (NEC) is one of the major 
causes of neonatal mortality (at least 20–30%) and mor-
bidity in very-low-birth-weight (VLBW) infants, defined 
as infants with a birth weight <1,500 g  [1] . Different fac-
tors are responsible for the development of NEC. In pre-
mature infants, colonization of the gut with probiotic or-
ganisms such as bifidobacteria and lactobacilli is poor and 
often delayed; there may be a shift to potentially patho-
genic bacteria due to delivery by cesarean section, delayed 
breastfeeding or empirical antibiotic treatment after birth 
 [2] . In recent decades, administration of probiotics con-
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 Abstract 
 Background: The use of probiotics as prophylaxis for necro-
tizing enterocolitis (NEC) in preterm infants is being increas-
ingly practised.  Objective: We report, for the first time, a case 
series of 3 preterm, very-low-birth-weight (VLBW) infants 
who developed bacteremia with  Bifidobacterium longum on 
probiotic therapy with Infloran ® containing viable  B. longum. 
 Methods: We retrospectively reviewed data of  3 infants (of 
gestational age <30 weeks and birth weight <1,230 g). They 
were admitted to the neonatal intensive care unit. Clinical 
data were retrieved from their medical records.  Results: In 
infants 1 and 2,  B. longum was isolated from the blood cul-
tures when they were on probiotic therapy with Infloran or 
shortly after, respectively, and was interpreted as transient 
bacteremia. The clinical presentation of these infants did not 
require antibiotic treatment after the isolation of  B. longum . 
Infant 3 developed an NEC despite probiotic therapy with In-
floran and the blood cultures showed  B. longum growth. This 
infant required explorative laparotomy and antibiotic treat-
ment. The clinical isolates of  B. longum and the strain of the 
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taining viable microorganisms was introduced. Probiot-
ics are thought to promote the colonization of the gut 
with beneficial microbial flora, prevent the colonization 
of pathogens, improve the maturity and function of the 
gut mucosal barrier and modulate the immune system 
 [2] . Based on these properties, probiotics are being in-
creasingly used to prevent NEC in VLBW infants and 
have been shown to reduce both the incidence and the 
all-cause mortality of NEC  [3] .
 In our clinical care, since 2007, the probiotic Infloran ® 
is given to all preterm (gestational age <32 weeks) and/or 
VLBW infants. Usually, probiotics are given for a dura-
tion of 2 weeks, starting from the first day of life in infants 
not on antibiotics or after antibiotic treatment has been 
discontinued. Up to now, treatment with probiotics has 
appeared to be safe. However, isolated cases of probiotic 
sepsis in infants in neonatal intensive care units have been 
reported  [4, 5] . We present, for the first time, a case series 
of 3 premature infants, who developed a  Bidifobacterium 
longum  bacteremia under therapy with a probiotic (Inflo-
ran; Desma Healthcare SpA, Torino, Italy) containing vi-
able  B. longum  and  Lactobacillus acidophilus adminis-
tered for the prevention of NEC.
 Methods 
 This is a retrospective case description of 3 infants admitted to 
the neonatal intensive care unit between July and December 2012 
at the University Hospital of Zurich, Zurich, Switzerland. Clinical 
data were retrieved from the patients’ medical records. A written 
informed consent was obtained from the parents.
 Microbiological analyses were performed as follows. Blood cul-
tures (BacT/ALERT FA aerobic ® , bioMérieux, Marcy-l’Etoile, 
France) were aerobically incubated at 37   °   C for 6 days. Bacterial 
strains were identified by conventional biochemical methods, ma-
trix-assisted laser desorption ionization time-of-flight mass spec-
trometry (MALDI-TOF MS) with the MALDI Biotyper software 
package (version 3.0) with reference database V.3.1.2.0 (Bruker 
Daltonik GmbH, Bremen, Germany) and by molecular analyses of 
partial 16S rRNA gene  [6] . An 800-bp 16S rRNA gene fragment 
including conserved and hypervariable regions was sequenced. 
Antibiotic susceptibility testing was performed with Etest strips 
(AB bioMérieux).
 Results 
 Clinical Course 
 Patient 1 
 A preterm girl presented with mild respiratory distress 
and required respiratory assistance during the first 9 days 
of life ( table 1 ). A hemodynamically nonsignificant per-
sistent ductus arteriosus closed under treatment with in-
domethacin (dosage 0.1 mg/kg/day on days 3–8). On day 
1, enteral feeding was started as well as Infloran adminis-
tration ( fig. 1 ). On day 6, she developed apneic episodes, 
suggesting a nosocomial infection. Antibiotic treatment 
with flucloxacillin and gentamicin was initiated empiri-
cally and stopped after 48 h as the blood cultures re-
mained negative ( fig. 1 ). On day 13, the baby developed 
local periumbilical redness with a small amount of pus. 
Flucloxacillin and gentamicin were instituted empirical-
ly.  Staphylococcus aureus was cultured from the umbilical 
pus, but the blood cultures remained negative. On day 20, 
the girl presented with marbled, pale skin and a slightly 
distended abdomen. Antibiotic treatment was continued 
for 48 h. A cerebrospinal fluid evaluation was negative; 
however, in the blood cultures obtained on day 20,  B. 
longum growth was observed on day 23.  The baby im-
proved and blood cultures taken on  day 27 remained neg-
ative. She displayed a complicated clinical course with se-
quential antibiotic therapy, so the probiotic Infloran was 
continuously administered from birth to day 28. The 
baby was discharged home without further complica-
tions.
 Patient 2 
 A preterm boy was intubated and given surfactant 10 
min after birth. His respiratory course was complicated 
with 3 episodes of mechanical ventilation during the first 
month, supplemental oxygen up to day 63 and the devel-
opment of moderate bronchopulmonary dysplasia ( ta-
ble 1 ). Amoxicillin and gentamicin were started empiri-
cally at birth and stopped after 48 h as the blood cultures 
were negative and the baby had no signs of sepsis ( fig. 1 ). 
Enteral feeding was started on day 1 ( table 1 ). From day 
3, the probiotic Infloran was administered for the preven-
tion of NEC and discontinued on day 17. Nosocomial in-
fection was suspected on day 20 and therefore the central 
line was removed. Blood cultures were taken and empiri-
cal antibiotic treatment with amoxicillin and gentamicin 
was initiated for 48 h. On day 23, the blood cultures taken 
on day 20 displayed  B. longum growth but the baby was 
stable . The boy remained asymptomatic and was dis-
charged home without needing supplemental oxygen.
 Patient 3 
 A preterm girl had an uncomplicated adaptation after 
the application of nasal continuous positive airway pres-
sure for the first 2 days ( table 1 ). From the first day of life, 
enteral feeding and administration of the probiotic Inflo-
ran were initiated ( fig. 1 ). On day 11, she suddenly dete-
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riorated, with clinical signs of acute NEC confirmed by 
pneumatosis on X-ray. Amoxicillin clavulanic acid and 
gentamicin were started empirically; enteral feeding and 
probiotics were discontinued. Explorative laparotomy 
was undertaken which confirmed the diagnosis of ex-
tended NEC stage III (according to the modified Bell stag-
ing criteria  [7] ). Resection of 23 cm of small bowel was 
performed on day 11. On day 14, growth of B. longum was 
detected in the blood cultures taken on day 11. The baby 
had a complicated postoperative course with serial lapara-
tomy, parenteral nutrition and delayed enteral feeding.
 Microbiological Analyses 
 For comparison, the Infloran capsule was inoculated 
on Brucella agar.  Bifidobacterium spp. were identified 
from the blood and the Infloran capsule based on typical 
pleomorphic Gram staining and biochemical reactions 
(acidification of glucose, saccharose, maltose and fruc-
 Table 1.  Demographic data of 3 patients
Patient 1 Patient 2 Patient 3
Gestational age, weeks 30 28 29 
Birth weight, g 1,200 850 1,230
Birth mode Cesarean section Cesarean section Cesarean section
Reason for prematurity Maternal preeclampsia Premature prolonged rupture of 
membranes for 6 days, 
chorioamnionitis (confirmed on histology)
Chorioamnionitis (confirmed 
on histology)
Apgar score at 1, 5 and 10 min 8, 9, 8 2, 5, 5 6, 6, 7
Enteral feeding Breast and formula milk (Prematil HA®); 
parenteral feeding
Breast and formula milk 
(Prematil HA®)
Breast and formula milk
(Prematil HA®)
Respiratory assistance Supplemental oxygen, nCPAP Mechanical ventilation, surfactant, 
supplemental oxygen
nCPAP
Other management Indomethacin for persistence of ductus 
arteriosus
– Bowel resection due to short 
bowel syndrome
Outcome Discharge at gestational age 36 weeks 
and body weight 2,030 g
Discharge at gestational age 39 weeks 
and body weight 2,890 g
Discharge after 11 months and 
with a body weight of 9,895 g, 
with parenteral nutrition
 nCPAP = Nasal continuous positive airway pressure.
 Fig. 1. Clinical courses of 3 preterm infants 
with  B. longum bacteremia. Illustration of 
the blood culture results in relation to the 
administration of probiotics (containing 
 B. longum ) and antibiotics to 3 preterm 
 infants with bacteremia due to  B. longum . 
⚪ = Negative blood cultures. ⚫ = Positive 
blood cultures. The asterisk marks the iso-
lation of  B. longum . Empirical antibiotic 
treatment consisted of flucloxacillin and 
gentamicin on days 6–8 and 13–22 in pa-
tient 1, amoxicillin and gentamicin on days 
1–3 and 20–22 in patient 2 and amoxicillin 
clavulanic acid and gentamicin from day 11 
in patient 3. NI = Nosocomial infection. 
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tose but no acidification of xylose and mannose). Analy-
sis of all isolates by MALDI-TOF MS revealed identifica-
tion as  B. longum  with a score of >2.0, which allows for 
species assignment. The bifidobacteria isolates derived 
from the clinical samples and the Infloran capsule had a 
100% 16S rRNA gene sequence similarity. Antibiotic sus-
ceptibility testing revealed a minimal inhibitory concen-
tration of 0.094 mg/l for penicillin.
 Discussion 
 To our knowledge, this is the first report of a case series 
of the development of bacteremia in VLBW infants that 
can be attributed to the probiotic strain  B. longum . For 
patients 1 and 2, the positive blood cultures with  B. long-
um were interpreted as transient bacteremia rather than 
septicemia. For patient 3, we have to speculate whether 
the  B. longum bacteremia was the consequence or the 
cause of the NEC with perioperative hematogenous dis-
semination of the bacteria. Nevertheless, the bifidobacte-
ria obtained from the patient samples and the Infloran 
capsule displayed an identical genetic and biochemical 
profile, suggesting a direct correlation between the ad-
ministration of probiotics and bacteremia in all 3 VLBW 
infants.
 In a very recent Cochrane report including random-
ized controlled trials, the evidence for probiotics in pre-
venting NEC and all-cause mortality in preterm infants 
was strongly supported and implied a change in practice 
 [3] . Moreover, Härtel et al.  [8]  demonstrated the benefit 
of probiotics in the VLBW infant population for reducing 
the gastrointestinal morbidity. In both studies, no probi-
otic systemic infections were observed; however, in the 
absence of clinical signs, an asymptomatic transient bac-
teremia with probiotic microorganisms could have been 
missed. Despite the strong evidence for the use of probi-
otics in preterm infants, there are concerns regarding its 
safety. The risk of bacterial transformation and possible 
infection by probiotic strains has to be examined  [9] . For 
safety reasons, both the European and the American 
Committees on Nutrition  [2, 9] have underlined the need 
for large, well-designed multicenter trials before the 
widespread use of probiotics in VLBW infants can be rec-
ommended.
 The occurrence of sepsis due to probiotics is not a 
novelty; there are reports of sepsis due to lactobacilli in 
groups of pediatric and adult patients  [10] . Over a 5-year 
period with a total of 681 blood cultures obtained from 
neonates at our hospital, we detected  B. longum bactere-
mia only in the 3 (0.4%) cases reported here. The blood 
culture systems used nowadays largely allow for accu-
rate detection of this fastidious Gram-positive rod, so an 
underestimation seems unlikely. We are not able to con-
clude whether the probiotic strain  B. longum was associ-
ated only with bacteremia or indeed caused an infection 
with NEC in patient 3. Nevertheless, our data docu-
menting probiotic bacteremia in preterm neonates ne-
cessitate caution with the use of probiotics in this vul-
nerable population. 
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